



Orally Disintegrating Films—Pharmaceutical Development for Improved Bioperformance

Guest Editor:

Prof. Dr. Jelena Parojčić

University of Belgrade, Belgrade,
Serbia

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

Orally disintegrating films (ODFs) have emerged as innovative oral dosage forms which may combine flexible dosing and a high level of medication adherence, thus meeting the criteria for patient-centric drug product design. Although their potential advantages in pharmacotherapy are well recognized, there is still a lot of research work to be done in order to explore and understand the complex relationship among different formulation factors, film mechanical properties, and their bioperformance.

This Special Issue aims to compile the most recent findings related to ODF development and characterization and extend the knowledge base, which would facilitate future product development. Contributions related to different aspects of ODF development, including different approaches to increase drug load and incorporate poorly soluble drugs; applicability of different manufacturing methods and their potential scale-up to industrial level; development of relevant *in vitro*, *in vivo*, and *in silico* methods for ODF characterization and bioperformance prediction are welcomed.

Prof. Dr. Jelena Parojčić

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[@MDPIpharma](https://twitter.com/MDPIpharma)